Latest News and Press Releases

TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...

MAPS names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors, bringing decades of drug policy expertise.

PharmAla announces completion of onboarding for its US distribution centre and resignation of its Chief Operating Officer.

Psycan discloses troubling statistics showing that Health Canada has begun to deny numerous doctor requests for MDMA and Psilocybin

SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve...

PharmAla incorporates a new entity in Australia to take advantage of tax incentives, and appoints Dr. Evan Lewis to its clinical advisory board.

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs: Market Share, and Growth Analysis by Product Type (LSD, Psilocybin, MDMA, Ketamine), Application, End User, Technology" has been...

PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results